This study examined the effects of low-dose tertiary prophylaxis on adults with severe hemophilia A, focusing on patients aged 18 to 60 who had existing joint issues.*
-
Researchers observed 22 patients during one year of on-demand treatment followed by one year of low-dose prophylaxis using plasma-derived factor 8 concentrates given 2-3 times a week.*
-
Results showed a significant reduction in annual bleeding frequency by 72.7%, improvements in joint health, and enhanced daily living activities, indicating better overall quality of life for participants.*